Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Griesinger, Frank; Curigliano, Giuseppe; Thomas, Michael; Subbiah, Vivek; S. Baik, Christina; S.W. Tan, Daniel; Lee, Daniel; Misch, D; Garralda, Elena; Kim, D.-W.; J. van der Wekken, Anthonie; F. Gainor, Justin; Paz‐Ares, Luis; V. Liu, Stephen; P. Kalemkerian, Gregory; Houvras, Yariv; W. Bowles, Daniel; S. Mansfield, Aaron; Marston Linehan, W.; Smoljanović, Vlatka; Rahman, Ahmadur; Kong, Shengchun; Zalutskaya, Alena; Louie-Gao, Melinda; Boral, Andy; Mazières, Julien

doi:10.1016/j.annonc.2022.08.002

Public

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Published in Annals of Oncology • Aug 13, 2022

Authors:

Frank Griesinger

Giuseppe Curigliano

Michael Thomas

Abstract

BACKGROUND: RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor, previously demonstrated clinical activity in patients with RET fusion-positive NSCLC in the phase I/II ARROW study, inclu...

Subject

Medicine

Internal medicine

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!